share_log

AbbVie | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

AbbVie | 11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

艾伯維公司 | 11-K:員工持股年度報告
美股sec公告 ·  06/27 17:04
Moomoo AI 已提取核心訊息
AbbVie Inc., a biopharmaceutical company, has filed its Form 11-K annual report with the Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The report details the financial statements of the AbbVie Savings Plan, which is an employee stock purchase, savings, and similar plan. The independent audit, conducted by Ernst & Young LLP, concluded that the financial statements present fairly the net assets available for benefits and the changes in net assets for the year in accordance with U.S. generally accepted accounting principles. The AbbVie Savings Plan's net assets available for benefits increased from $10,305,327 in 2022 to $11,727,168 in 2023. The report includes a summary of the Plan's provisions, contributions, investment options, and distributions, as well as the Plan...Show More
AbbVie Inc., a biopharmaceutical company, has filed its Form 11-K annual report with the Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The report details the financial statements of the AbbVie Savings Plan, which is an employee stock purchase, savings, and similar plan. The independent audit, conducted by Ernst & Young LLP, concluded that the financial statements present fairly the net assets available for benefits and the changes in net assets for the year in accordance with U.S. generally accepted accounting principles. The AbbVie Savings Plan's net assets available for benefits increased from $10,305,327 in 2022 to $11,727,168 in 2023. The report includes a summary of the Plan's provisions, contributions, investment options, and distributions, as well as the Plan's tax status and subsequent events. The Plan is fully compliant with the Employee Retirement Income Security Act of 1974 (ERISA) and offers a variety of investment options, including AbbVie common shares. The Plan's investments are subject to market risks, and the Plan may be terminated at any time by AbbVie, although there are no current intentions to do so. The Plan's tax-exempt status has been affirmed by the IRS, and there are no uncertain tax positions that would require recognition of a tax liability.
生物製藥公司AbbVie Inc.已向美國證券交易委員會(SEC)提交了其11-K表格的年度報告,截至2023年12月31日財年結束。報告詳細說明了AbbVie儲蓄計劃的財務報表,該計劃是員工股票購買、儲蓄和類似計劃。由安永會計師事務所進行的獨立審計得出結論,該財務報表符合美國通用會計原則,公正地呈現了可用於福利的經淨資產和該年淨資產的變化。AbbVie儲蓄計劃的可用於福利的淨資產從2022年的103,053,270美元增加到2023年的117,271,680美元。報告包括計劃條款、貢獻、投資選項和分配的摘要,以及計劃的稅收狀態和後續事件。該計劃完全符合1974年僱員退休收入安全法案(ERISA)的規定,提供多種投資選項,包括AbbVie普通股。該計劃的投資面臨市場風險,AbbVie可以隨時終止該計劃,儘管當前沒有這樣做的意向。該計劃的免稅地位得到了稅務部門的批准,沒有不確定的稅收立場需要確認稅務負債。
生物製藥公司AbbVie Inc.已向美國證券交易委員會(SEC)提交了其11-K表格的年度報告,截至2023年12月31日財年結束。報告詳細說明了AbbVie儲蓄計劃的財務報表,該計劃是員工股票購買、儲蓄和類似計劃。由安永會計師事務所進行的獨立審計得出結論,該財務報表符合美國通用會計原則,公正地呈現了可用於福利的經淨資產和該年淨資產的變化。AbbVie儲蓄計劃的可用於福利的淨資產從2022年的103,053,270美元增加到2023年的117,271,680美元。報告包括計劃條款、貢獻、投資選項和分配的摘要,以及計劃的稅收狀態和後續事件。該計劃完全符合1974年僱員退休收入安全法案(ERISA)的規定,提供多種投資選項,包括AbbVie普通股。該計劃的投資面臨市場風險,AbbVie可以隨時終止該計劃,儘管當前沒有這樣做的意向。該計劃的免稅地位得到了稅務部門的批准,沒有不確定的稅收立場需要確認稅務負債。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息